利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.028 秒)

    DELIVERY OF HYDROPHOBIC ACTIVE AGENT PARTICLES
    2.
    发明申请
    DELIVERY OF HYDROPHOBIC ACTIVE AGENT PARTICLES 审中-公开

    公开(公告)号：US20200237971A1

    公开(公告)日：2020-07-30

    申请号：US16847272

    申请日：2020-04-13

    申请人： Surmodics, Inc.

    发明人： Joram Slager ,  Toni M. Heyer ,  David E. Babcock

    IPC分类号： A61L29/08 ,  C12N15/113 ,  A61M25/10 ,  A61K47/34 ,  A61K31/713 ,  A61K31/337 ,  A61L29/14 ,  A61L29/16

    摘要： Embodiments of the invention include drug delivery coatings and devices including the same. In an embodiment, the invention includes a drug delivery coating including a polymeric layer. The polymeric layer can include a hydrophilic outer surface. The coating can also include a matrix contacting the hydrophilic outer surface. The matrix can include a particulate hydrophobic therapeutic agent and a cationic agent. The polymeric layer can further include a hydrophilic polymer having pendent photoreactive groups and a photo-crosslinker including two aryl ketone functionalities. Other embodiments are also included herein.

    SOLVENT METHODS FOR PREPARING CRYSTALLINE MACROLIDE PARTICULATES, COMPOSITIONS, AND ARTICLES CONTAINING PARTICULATES
    4.
    发明申请
    SOLVENT METHODS FOR PREPARING CRYSTALLINE MACROLIDE PARTICULATES, COMPOSITIONS, AND ARTICLES CONTAINING PARTICULATES 有权
    用于制备晶体结构的颗粒，组合物和含有颗粒物的制品的溶剂方法

    公开(公告)号：US20150017219A1

    公开(公告)日：2015-01-15

    申请号：US14303309

    申请日：2014-06-12

    申请人： SURMODICS, INC.

    发明人： Joram Slager ,  Aleksey V. Kurdyumov ,  Toni M. Heyer

    IPC分类号： A61L29/16 ,  C07D498/18

    CPC分类号： A61L29/16 ,  A61K9/0019 ,  A61K9/14 ,  A61K31/436 ,  A61L2300/416 ,  C07D498/18 ,  Y10T428/2982

    摘要： The invention provides therapeutic particulates including a macrolide, such as rapamycin, in solid state crystalline form, having a size of 20 μm or less, or 10 μm or less. The particulates are formed in one method by preparing a composition with a macrolide and first (e.g., xylene) and second (e.g., an alcohol, acetone, or acetonitrile) solvents. In the composition a maximum solubility for the macrolide that is greater than a maximum solubility of the macrolide dissolved in either the first or second solvent individually. The first and second solvents are then evaporated from the composition to provide the macrolide particulates. In another method, the particulates can be formed by a method including sonication and stirring/evaporation steps, and the particulates can be obtained from a supersaturated solution, formed during the process. Particulates display desirable low polydispersity, and can be used in therapeutic compositions, or can be associated with an implantable or insertable medical device for the treatment of a subject.

    摘要翻译： 本发明提供治疗性微粒，其包括固体状结晶形式的大环内酯如雷帕霉素，其尺寸为20μm或更小或10μm或更小。 通过制备具有大环内酯和第一（例如二甲苯）和第二（例如醇，丙酮或乙腈）溶剂的组合物来形成颗粒。 在组合物中，大环内酯的最大溶解度大于单独溶解在第一或第二溶剂中的大环内酯的最大溶解度。 然后将第一和第二溶剂从组合物中蒸发以提供大环内酯颗粒。 在另一种方法中，颗粒可以通过包括超声处理和搅拌/蒸发步骤的方法形成，并且颗粒可以从在过程中形成的过饱和溶液获得。 颗粒显示出期望的低多分散性，并且可以用于治疗组合物，或者可以与用于治疗受试者的可植入或可插入的医疗装置相关联。

    SOLVENT METHODS FOR PREPARING CRYSTALLINE MACROLIDE PARTICULATES, COMPOSITIONS, AND ARTICLES CONTAINING PARTICULATES
    6.
    发明申请
    SOLVENT METHODS FOR PREPARING CRYSTALLINE MACROLIDE PARTICULATES, COMPOSITIONS, AND ARTICLES CONTAINING PARTICULATES 审中-公开

    公开(公告)号：US20180071436A1

    公开(公告)日：2018-03-15

    申请号：US15714298

    申请日：2017-09-25

    申请人： SURMODICS, Inc.

    发明人： Joram Slager ,  Aleksey V. Kurdyumov ,  Toni M. Heyer

    IPC分类号： A61L29/16 ,  A61K9/14 ,  C07D498/18

    CPC分类号： A61L29/16 ,  A61K9/0019 ,  A61K9/14 ,  A61K31/436 ,  A61L2300/416 ,  C07D498/18 ,  Y10T428/2982

    摘要： The invention provides therapeutic particulates including a macrolide, such as rapamycin, in solid state crystalline form, having a size of 20 μm or less, or 10 μm or less. The particulates are formed in one method by preparing a composition with a macrolide and first (e.g., xylene) and second (e.g., an alcohol, acetone, or acetonitrile) solvents. In the composition a maximum solubility for the macrolide that is greater than a maximum solubility of the macrolide dissolved in either the first or second solvent individually. The first and second solvents are then evaporated from the composition to provide the macrolide particulates. In another method, the particulates can be formed by a method including sonication and stirring/evaporation steps, and the particulates can be obtained from a supersaturated solution, formed during the process. Particulates display desirable low polydispersity, and can be used in therapeutic compositions, or can be associated with an implantable or insertable medical device for the treatment of a subject.